Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/08—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
  • C07D487/18—Bridged systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
  • C07D471/18—Bridged systems

Definitions

• the invention relates to nitrogen-containing heterocyclic compounds, their preparation and their use as antibacterial drugs.
• the Applicant has discovered novel related compounds, having outstanding antibacterial properties quite unexpected. These compounds more particularly have an excellent activity on Pseudomonas aeruginosa, a bacterial strain frequently encountered in nocosomal infections as well as in patients suffering from cystic fibrosis.
• the compounds of the invention have been active on models of animal infection, including strains usually resistant to commonly used antibiotics.
• the compounds of the invention are capable of counteracting the main mechanisms of resistance of bacteria such as ⁇ -lactamases, efflux pumps and porin mutations.
• the compounds of the invention correspond to formula (I), in their possible isomeric or diastereoisomeric forms, or mixtures:
• R 1 represents a hydrogen atom or a - (CH 2 ) m -NH 2 radical
• CH NH, wherein m is 1 or 2;
• R 2 and R 3 together form a nitrogenous heterocyclic ring with 5-membered aromatic atoms containing 1, 2 or 3 nitrogen atoms, substituted on a nitrogen atom by R 4 ;
• R 4 represents a hydrogen atom, a (C 1 -C 6 ) alk radical or a chain of formula: - (A) n - (NH) o - (CH 2 ) p - (CHR ') q R "
• R ' represents a hydrogen atom or a carboxy group;
• R represents a hydrogen atom or a NH 2, NH (Ci-C6) alk, N (CpC 6) alk 2, CONH 2, CONH (C r C 6) alk, CON (C r C 6) alk 2 , or a saturated 5- or 6-membered heterocyclic ring containing 1 or 2 nitrogen atoms and, if appropriate, another heteroatom selected from oxygen and sulfur, attached to the chain by a nitrogen atom or by a carbon atom and optionally substituted by a radical (CrC 6 ) alc; n, o and q represent 0 or 1 and p represents an integer of 0 to 4; R 5 represents a group OSO 3 H or OCFHCO 2 H or OCF 2 CO 2 H, with the proviso that: O - R 1 is other than hydrogen, - (CH 2 ) m --NH 2 , - (CH 2 ) m --NH (C, -C 6 ) alc or - (CH 2 ) m -
• radical (Ci-C 6 ) alkyl is meant in particular the methyl, ethyl, propyl, isopropyl, and butyl, pentyl or hexyl linear or branched.
• heterocycle with a 5-membered aromatic character containing 1, 2 or 3 nitrogen atoms we mean those chosen from the following list, the two bonds symbolizing the junction with the nitrogenous ring formed by R 2 and R 3 :
• saturated heterocycle with 5 or 6 vertices containing 1 or 2 nitrogen atoms and, where appropriate, an oxygen or sulfur atom is meant in particular a five-membered ring of pyrrolidine, imidazolidine or pyrazolidine type, or a 6-membered ring of piperidine, piperazine, morpholine or thiomorpholine type, the heterocycle being linked to the chain by a nitrogen atom or a carbon atom.
• acid salts of the products of formula (I) mention may be made inter alia of those formed with mineral acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric or phosphoric acids or with organic acids such as formic acid, acetic, trifluoroacetic, propionic, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, alkanesulfonic, such as methane and ethanesulphonic acids, arylsulfonic acids such as benzene and paratoluenesulphonic acids.
• mineral acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric or phosphoric acids
• organic acids such as formic acid, acetic, trifluoroacetic, propionic, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, alkanesul
• base salts of the products of formula (I) there may be mentioned, among others, those formed with inorganic bases such as, for example, * sodium, potassium hydroxide, lithium, calcium, magnesium or ammonium or with organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris (hydroxymethyl) aminomethane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine, or phosphonium salts, such as alkylphosphonium, arylphosphoniums, alkylarylphosphonium, alkenylarylphosphonium or quaternary ammonium salts such as tetra n-butylammonium salt.
• inorganic bases such as, for example, * sodium, potassium hydroxide, lithium, calcium
• the asymmetric carbon atoms contained in the compounds of formula (I) can independently of each other have the R, S or RS configuration and the compounds of formula (I) are thus in the form of pure enantiomers or pure diastereoisomers or in the form of a mixture of enantiomers, especially racemates, or mixtures of diastereoisomers.
• substituent Ri on the one hand and the chain -C (O) -NRs- on the other hand can be in cis and / or trans position with respect to the ring to which they are attached, the compounds of formula (I ) are in the form of cis isomers or trans isomers or mixtures.
• the subject of the invention is in particular those compounds in which R 2 and R 3 together form a pyrazolyl heterocycle.
• the subject of the invention is in particular those in which R
• the subject of the invention is also those in which R 4 represents a chain of formula - (A) n - (NH) o - (CH 2 ) p - (CHR ') q R as defined above, and especially those in which R 4 represents a chain of formula -C (O) -NH- (CH 2 ) p - (CHR ') q R "in which R', R", p and q are as defined above.
• the invention particularly relates to the compounds described later in the experimental part and in particular those whose names follow: trans-8- (aminomethyl) -2- (2-amino-ethyl) -carbamoyl) -4,8-dihydro-5- (sulfooxy) -4,7-methano-7H-pyrazolo [3,4-e] [1,3] diazepin-6 (5H) -one,
• Another subject of the invention is a process for the preparation of compounds of formula (I), characterized in that a compound of formula (II) is treated:
• R 'i represents a radical R] in which, where appropriate, the amino function (s) present are protected
• R' 2 and R ' 3 together form a nitrogenous heterocycle with aromatic character with 5 vertices containing 1, 2 or 3 nitrogen atoms and P represents a protecting group of the hydroxyl radical, in the presence of a base, with diphosgene, then with an amine of formula (III):
• R ' a and R' * ' are respectively R " and R" in which, where appropriate, the carboxy and amino reactive functions are protected, and p and q are as defined above, to obtain a compound of formula (IV):
• R " 1 and P are as defined above and R “" 2 and R “ “ 3 together form a nitrogenous heterocyclic ring with a 5-membered aromatic character containing 1, 2 or 3 nitrogen atoms, substituted on a nitrogen atom by a chain of formula -C (O) -NH- (CH 2 ) p - (CHR ' a ) q R'"in which R ' a , R'", p and q are such as defined above, then deprotects the hydroxyl radical and subjects the compound obtained to a sulfation reaction by the action of complexed SO 3 , or to the action of a reagent of formula Hal-CHF-CO 2 alc or of formula Hal- CF 2 -CO 2 alc, wherein HaI represents a halogen atom different from fluorine and ae represents an alkyl radical containing from 1 to 6 carbon atoms, in the presence of a base, and then to a hydrolysis of the ester of obtained alkyl,
• Another subject of the invention is a process for the preparation of compounds of formula (I), characterized in that a compound of formula (II) as defined above is treated with a base and then with a reagent of formula (V):
• R " 1 and P are as defined above and R " 2a and R “" 3a together form a nitrogenous heterocyclic ring with a 5-membered aromatic character containing 1, 2 or 3 nitrogen atoms, substituted on an atom of nitrogen by a chain of formula -SO 2 -NH-CH 2 ) p - (CHR “ a ) q R ' ' " in which R * a , R ' " , p and q are as defined above, then deprotects the hydroxy radical and continues the synthesis as described above.
• Another subject of the invention is a process for the preparation of compounds of formula (I), characterized in that a compound of formula (II) as defined above, if appropriate in the presence of a base, is treated. with a reagent of formula (VI): BC (O) - (NH) O - (CH 2 ) p - (CHR ' a ) q R'"(VI)
• R'i and P are as defined above and R "* 2b and R ' " 3b together form a nitrogenous heterocycle with a 5-membered aromatic character containing 1, 2 or 3 nitrogen atoms, substituted on a hydrogen atom, nitrogen by a chain of formula -C (O) - (NH) 0 - (CH 2) p - (CHR * a) q R "" wherein R ', R' ', o, p and q are as as defined above, then continues the synthesis as described above.
• Another subject of the invention is a process for the preparation of compounds of formula (I), characterized in that a compound of formula (II) as defined above, in the presence of a base, is treated with a reagent of formula (VII):
• Another subject of the invention is a process for the preparation of compounds of formula (I), characterized in that a compound of formula (II) as defined above is treated with a reagent of formula (VIII):
• R " 1 and P are as defined above and R “" 2d and R" " 3 together form a nitrogenous heterocyclic ring with a 5-membered aromatic character containing 1, 2 or 3 nitrogen atoms, substituted on one atom nitrogen by a chain of formula - (CO) -NH- (CH 2 ) p - (CHR ' a ) q R'"in which R * a , R "" , p and q are as defined above, then continue the synthesis described as above.
• Another object of the invention is a process for preparing compounds of formula (I), characterized in that the treating a compound of formula (H '):
• the prior protection of the amine function at R '1 and in the reagents of formulas III, V, VI, VII, VIII and IX is in particular carried out in the form of benzyl or tritylated derivatives, in the form of carbamates, in particular of allyl , benzyl, phenyl or tertbutyl, or in the form of silyl derivatives such as tertbutyl dimethyl, trimethyl, triphenyl or diphenylterbutyl-silyl derivatives, or else phenylsulfonylalkyl or cyanoalkyl derivatives.
• Deprotection can be performed by various methods known to those skilled in the art, depending on the nature of the protecting group. It may in particular be carried out by the action of "an acid, for example trifluoroacetic acid, the deprotected compound then being obtained as the acid salt. It can also be carried out by hydrogenolysis or using soluble complexes of Palladium O or by action of fluoride tetrabutyl ammonium or by reduction. An illustration is provided later in the experimental section.
• the prior protection of the carboxy at R'a in the reagents of formulas III, V, VI and VIII is in particular carried out in the form of ester derivatives, in particular alkyl, allyl, benzyl, benzhydryl or p-nitro benzyl derivatives.
• the deprotection can be carried out by various methods known to those skilled in the art, for example by saponification, acid hydrolysis, hydrogenolysis or cleavage using soluble complexes of Palladium 0.
• the prior protection of the hydroxy of the compound of formula (II) is carried out conventionally in the form of ethers, esters or carbonates.
• the ethers may be alkyl or alkoxyalkyl ethers, preferably methyl or methoxyethoxymethyl ethers, aryl or preferably aralkyl ethers, for example benzyl, or silylated ethers, for example derivatives thereof. silylated above.
• the esters may be any cleavable ester known to those skilled in the art and preferably acetate, propionate or benzoate or p-nitrobenzoate.
• the carbonates may be, for example, methyl, tert-butyl, allyl, benzyl or p-nitrobenzyl carbonates.
• the deprotection is carried out by the means known to those skilled in the art, in particular saponification, hydrogenolysis, cleavage with soluble complexes of palladium O, hydrolysis in an acidic medium or, for the silylated derivatives, the treatment with tetrabutylammonium fluoride.
• the base in the presence of which the compound of formula (II) and the diphosgene is reacted may for example be an amine such as triethylamine, but other bases known to those skilled in the art for such reactions may be used. It can be carried out in a solvent such as methylene chloride.
• the sulfation reaction is carried out by the action of SO 3 complexes such as SO 3 -pyridine or SO 3 -dimethylformamide, by operating in pyridine or in dimethylformamide, the salt formed, for example the pyridine salt, which can then be exchanged. for example by a salt of another amine, a quaternary ammonium or an alkali metal.
• SO 3 complexes such as SO 3 -pyridine or SO 3 -dimethylformamide
• Salification with acids is optionally carried out by adding an acid in the soluble phase to the compound.
• Salification with the bases of the sulfooxy function can be carried out using the amine salt and in particular pyridine obtained during the action of the SO 3 -amine complex and the other salts are obtained from this amine salt. It can in particular operate by ion exchange resin.
• the separation of enantiomers and diastereoisomers can be carried out according to the techniques known to those skilled in the art, in particular chromatography, on chiral phase or otherwise.
• the base in the presence of which the compound of formula (II) is reacted before the action of the reagent of formula (V) may for example be an alkaline hydride such as sodium hydride, but other known bases of those skilled in the art for reactions of this type may be used.
• the reaction can be carried out in tetrahydrofuran.
• the base in the presence of which the compound of formula (II) is reacted with the reagent of formula (VI) in which B represents a halogen may for example be an amine such as diisopropylethylamine or triethylamine. It can be carried out in dimethylformamide or dichloromethane.
• the conditions under which the compound of formula (II) is reacted with the reagent of formula (VI) in which B represents an OH are the classical conditions of peptide couplings known to those skilled in the art. Such conditions are illustrated later in the experimental section.
• the reaction of the compound of formula (II) with the reagent of formula (VIII) can be carried out in acetonitrile or a mixture with tetrahydrofuran.
• Reacting the compound of formula (II ') with the reagent of formula (IX) is carried out in the presence of trimethylphosphine and is carried out for example in tetrahydrofuran or tetrahydrofuran / toluene.
• the invention also relates to the intermediate compounds of formulas (IV), (IVa),
• the compounds of general formula (I) have excellent antibiotic activity on Pseudomonas aeruginosa as well as models of animal infection with strains resistant to antibacterial agents commonly used. This remarkable and unexpected antibiotic activity was not observed for compounds described in WO 04/052891 and in particular for structurally related compounds. This is illustrated below.
• respiratory tract infections eg acute pneumonia or chronic lower tract infections
• blood infections eg septicemia, acute or chronic urinary tract infections
• auditory system infections eg, malignant otitis externa, or chronic suppurative otitis
• those of the skin and soft tissues eg dermatitis, infected wounds, folliculitis, pyoderma, relapsing forms of acne, eyes, eg corneal ulcer, nervous system ulcers, including meningitis and brain abscesses
• heart infections such as endocarditis, bone and joint infections such as stenoarticular pyoarthrosis, osteomyelitis vertebral, pubic symphysitis
• gastrointestinal tract infections such as necrotizing enterocolitis and peri-rectal infections.
• the subject of the present invention is therefore also, as medicaments and especially antibiotic drugs, the compounds of formula (I) as defined above, in free form and in the form of zwitterions and salts with bases and acids. inorganic or organic pharmaceutically acceptable.
• the subject of the invention is, as medicaments, the compounds in which R 2 and R 3 together form a substituted pyrazolyl heterocycle.
• the invention more particularly relates, as medicaments, those in which R 1 represents a - (CH 2 ) m -NH 2 radical, as well as those in which R 1 represents a radical - (CH 2 ) m -NH-C (NH) NH 2 , m in each case being equal to 1.
• the subject of the invention is also, as medicaments, those in which R 4 represents a chain of formula - (A) n - (NH) o - (CH 2 ) p - (CHR ') q R "as defined above and especially those in which R 4 represents a chain of formula -C (O) -NH- (CH 2 ) p - (CHR') q R" in which R ' , R ", p and q are as defined above.
• the invention particularly relates, as medicaments, to the compounds described later in the experimental part and in particular those whose names follow: trans-8- (aminomethyl) -2- (2-Amino-ethyl-carbamoyl) -4,8-dihydro-5- (sulfooxy) -4,7-methano-7H-pyrazolo [3,4-e] [1,3] diazepin-6 (5H) - one,
• compositions containing, as active principle, at least one of the compounds according to the invention as defined above.
• compositions may be administered orally, rectally, parenterally, in particular intramuscularly, or locally by topical application to the skin and mucous membranes.
• compositions according to the invention can be solid or liquid and be in the pharmaceutical forms commonly used in human medicine, for example, single or coated tablets, capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the usual methods.
• the active ingredient (s) can be incorporated into excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non aqueous vehicles.
• excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non aqueous vehicles.
• compositions may in particular be in the form of a lyophilizate intended to be dissolved extemporaneously in a suitable vehicle, for example sterile, pyrogen-free water.
• a suitable vehicle for example sterile, pyrogen-free water.
• the dose administered varies according to the condition being treated, the subject, the route of administration and the product under consideration. It may be, for example, between 0.250 g and 10 g per day, orally in humans, with the product described in Example 1, 4 or 5, or between 0.25 g and 10 g per day intramuscularly or intravenously.
• the products of formula (I) can also be used as disinfectants for surgical instruments.
• the alcohol obtained in the preceding stage (1.73 g, 5.76 mmol) is dissolved in anhydrous pyridine (35 ml) under nitrogen, at 0 ° C. Then methanesulfonyl chloride (1.78 ml, 23 mmol) is added dropwise. After stirring for 2.5 hours at room temperature, the reaction mixture is treated with a saturated aqueous solution of ammonium chloride (100 mL) and then extracted with ethyl acetate. The combined organic phases are then washed 5 times with saturated aqueous ammonium chloride solution, dried over sodium sulphate, filtered and then concentrated in vacuo to give the expected dimesylated derivative in the form of a yellow oil.
• the dimesylated intermediate is dissolved in anhydrous dimethylformamide (45 ml), under nitrogen, in the presence of sodium azide (1.12 g, 17.3 mmol).
• the reaction mixture is heated at 70 ° C. for 24 hours. If necessary 1 eq. Azide is added for the conversion to be complete.
• the reaction is complete, the mixture is treated with a 10% aqueous solution of NaH 2 PO 4 (100 mL) and then extracted with dichloromethane. The combined organic phases are dried over sodium sulfate, filtered and then concentrated in vacuo to give the expected azide as a yellow oil.
• the aqueous phase is extracted with dichloromethane (15 mL).
• the organic phases are combined, washed with a saturated solution of NaCl, dried over MgSO 4 , concentrated in vacuo to give, after chromatography on a silica column (gradient eluent C ⁇ 2 Cl 2 / ethyl acetate 90/10 to 80/20 ), the expected derivative (86mg, 0.147mmol, 35%).
• the derivative obtained in the preceding stage (134 mg, 0.229 mmol) is dissolved in dimethylformamide (0.33 mL) and dichloromethane (0.98 mL). 10% palladium on carbon at 50% water (73 mg, 0.034 mmol) is added. After three vacuum / nitrogen purges, the reaction mixture is placed under a hydrogen atmosphere until the ⁇ -PLC starting material disappears. The mixture is then concentrated under vacuum and then coevaporated three times with anhydrous dichloromethane, finally dried under vacuum in the presence of P 2 O 5 for 2h, to give the expected debenzylated intermediate.
• the debenzylated derivative is taken up in anhydrous pyridine (0.9 ml) in the presence of the pyridine / trioxide sulphide complex (73 mg, 0.458 mmol).
• the reaction mixture is stirred at room temperature until complete conversion to HPLC, and then concentrated to dryness after treatment with the addition of water.
• the crude reaction product is chromatographed on a silica column (gradient eluent CH 2 Cl 2 / MeOH 100/0 to 85/15 by 5%) to give the expected salt (79 mg, 0.121 mmol, 53%).
• a suspension of 10 g of DOWEX 50WX8 resin in a 2N sodium hydroxide solution (5OmL) is stirred for 1 h and then poured onto a chromatographed column.
• the column is conditioned with demineralized water until neutral, then with a water / T ⁇ F 90/10 mixture.
• the salt obtained in the preceding stage (79 mg, 0.121 mmol) is dissolved in a minimum of methanol, deposited on the column and then eluted with a water / T ⁇ F 90/10 mixture.
• the fractions containing the substrate are combined and frozen.
• the frozen solution is lyophilized to yield the expected sodium salt (65mg, 0.109mmol, 90%) as a beige solid.
• a solution of trifluoroacetic acid (2.4mL) in dichloromethane (2.4mL) is added dropwise to a solution of the sodium salt obtained in the preceding stage (42mg, 0.092mmol) in dichloromethane (1.2mL) under nitrogen and cooled. at 0 ° C.
• the reaction is stirred for 1 h at room temperature.
• the mixture is evaporated to dryness.
• the residue is taken up in water (3 ml) and the solution is washed with diethyl ether (3 ml).
• the aqueous solution is frozen and then lyophilized to give the expected sodium salt and trifluoroacetate (62 mg, 0.099 mmol, 94%) as a beige solid.
• Step C of Example 1 the derivative obtained in the preceding stage (150 mg, 0.376 mmol), dichloromethane (20 mL), triethylamine (105 ⁇ L, 0.751 mmol), diphosgene (68 ⁇ L, 0.563 mmol) and N-Boc-piperazine (21 Omg, 1.13 mmol), after chromatography on a silica column (gradient eluent C 2 Cl 2 / ethyl acetate 80/20 to 70/30), give the expected derivative (145 mg, 0.237 mmol , 63%) as a beige solid.
• Step D of Example 1 the derivative obtained in the preceding stage (145 mg, 0.237 mmol), dimethylformamide (0.34 mL), dichloromethane (1.OmL) and palladium 10% on carbon at 50% in water (76mg, 0.036mmol) lead to the expected debenzylated intermediate.
• Step C of Example 1 the derivative obtained in Step B of Example 1 (228 mg, 0.571 mmol), dichloromethane (30 mL), triethylamine (159 ⁇ L, 1.14 mmol), diphosgene (103 ⁇ L , 0.856 mmol) and N, N-dimethyl-ethylenediamine (317 ⁇ L, 2.85 mmol) lead, after chromatography on a silica column (gradient eluent C ⁇ 2 Cl 2 / MeO ⁇ 100/0 to 95/5 by 1%), to the derivative expected (193mg, 0.375mmol, 66%) as a yellow solid.
• Step D of Example 1 the derivative obtained in the preceding stage (173 mg, 0.337 mmol), dimethylformamide (0.48 ml), dichloromethane (1.44 ml) and palladium 10% on carbon at 50% by weight are used. water (108mg, 0.051mmol) lead to the expected debenzylated intermediate.
• Step C of Example 1 the derivative obtained in Step B of Example 1 (250 mg, 0.626 mmol), dichloromethane (32.8 ml), triethylamine (174 ⁇ l), diphosgene (113 ⁇ l) and N-Boc-1,3-propanediamine (382 ⁇ L) leads after a reaction time of 3 h 30 ( ⁇ 40% conversion) and chromatography on a silica column (gradient eluent C 2 Cl 2 / AcOEt 100/0 to 70/30). ), the expected derivative (132mg, 0.22mmol, 35%).
• Step D of Example 1 the derivative obtained in the preceding stage (132 mg, 0.22 mmol), the mixture dimethylformamide / dichloromethane 1/3 (2.5 mL) and palladium 10% on carbon at 50% water (53 mg) lead to the expected debenzylated intermediate.
• the salt obtained in the previous step (90mg, 0.134mmol), DOWEX 50WX8 (Hg) and 2N sodium hydroxide (55ml) lead after elution with water and lyophilization only the expected sodium salt (48mg, 0.078mmol, 58%) as a white powder.
• Step C of Example 1 the derivative obtained in Step B of Example 1 (250 mg, 0.626 mmol), dichloromethane (32.8 ml), triethylamine (174 ⁇ l), diphosgene (13 ⁇ l) and N-Boc-1,3-butanediamine (419 ⁇ L), after a reaction time of 3 h 30 (-50% conversion) and chromatography on a silica column (gradient eluent C ⁇ 2 Cl 2 / AcOEt 100/0 to 70 / 30), the expected derivative (91 mg, 0.148 mmol, 24%).
• Step D of Example 1 the derivative obtained in the preceding stage (91 mg, 0.15 mmol), the mixture dimethylformamide / dichloromethane 1/3 (1.7 ml) and palladium 10% on carbon at 50% water. (36 mg) lead to the expected debenzylated intermediate.
• Step A trans [[2- (Carbamoylmethyl-carbamoyl) -4,5,6,8-tetrahydro-6-oxo-5- (phenylmethoxy) -4,7-methano-7H-pyrazolo [3,4-e] ] [1,3] diazepin-8-yl] methyl] -carbamate 1,1-dimethylethyl
• Step C the derivative obtained in Step B of Example 1 (200 mg, 0.501mmol), dichloromethane (26mL), triethylamine (0.489mL, 3.507mmol), diphosgene (0.09ImL, 0.751mmol) and glicinamide hydrochloride salt (0.277mg, 2.50mmol) lead after 2h of reaction and chromatography.
• Step 4 trans [[2- (Dimethylaminosulfamoyl) -4,5,6,8-tetrahydro-6-oxo-5- (phenylmethoxy) -4,7-methano-7H-pyrazolo [3,4-e] [1, 3] diazepin-8-yl] methyl] -carbamate 1,1-dimethylethyl
• the derivative obtained in Step B of Example 1 200 mg, 0.500 mmol
• anhydrous tetrahydrofuran 7 ml
• 60% sodium hydride in oil (30mg, 0.751mmol) is added in one portion.
• the dimethylsulfamoyl chloride 160 ⁇ L, 1.502 mmol is added dropwise. The temperature of the mixture is progressively raised to ambient temperature. After stirring for 3 h, the medium is hydrolyzed and extracted with dichloromethane (10 mL). The aqueous phase is extracted with dichloromethane (10 mL). The combined organic phases are washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, concentrated under reduced pressure to give, after chromatography on a silica column (gradient eluent C ⁇ 2 Cl 2 / MeO ⁇ 100/0 to 98 / 2), the expected derivative (98mg, 0.193mmol, 39%) in the form of a white powder.
• Step D of Example 1 the derivative obtained in the preceding stage (90 mg, 0.178 mmol), dimethylformamide (0.26 ml), dichloromethane (0.79 ml) and the 10% palladium on charcoal at 50% water (57mg, 0.027mmol) lead to the expected debenzylated intermediate.
• Example 9 sodium salt and trifluoroacetate of trans [[8- (aminomethyl) -1-
• Example 10 Sodium salt and trifluoroacetate salt of trans-8- (aminomethyl) -2- (carbamoyloyl ) -4,8-dihydro-5- (sulfooxy) -4,7-methano-7H-pyrazoloF3 4-e] [1, 3] diazepin-6 (5H) -one
• Example 11 Sodium salt and trifluoroacetate salt of trans-8- (amino-methyl) -4,8-dihydro-2- (piperidine-4-carbonyl) -5- (sulfooxy) -4,7-methano-7H- pyrazolof 3,4-e] [1,31 diazepin-6 (5HV one
• N-boc-isonipecotic acid (0.137 g, 0.1 mmol) is dissolved in dimethylformamide (3 mL) in the presence of diisopropylethylamine (0.297 mL, 0.1 mmol) and then 0- (1-benzotriazol-1-tetrafluoroborate.
• yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (0.211g, O. ⁇ mmol) was added followed pyrazole obtained in step B of example 1 (239mg, O. ⁇ mmol) dissolved in dimethylformamide ( IML).
• the stirring is maintained at room temperature for 1 h and then the reaction mixture is hydrolyzed with water (15 mL) and extracted with ethyl acetate (30 mL). The organic phase is washed 5 times with water (15 ml), dried over magnesium sulphate and then concentrated under vacuum.
• the crude reaction product is chromatographed on a column of "silica (eluant cyclohexane / ethyl acetate 80/20 and then 70/30) to yield the expected derivative (0.219g, 0.36mmol, 60%) as an oil.
• Step E of Example 1 the derivative obtained in the preceding stage (61 mg, 0.09 mmol), DOWEX 50WX8 resin (9.4 g) and 2N sodium hydroxide (50 mL) lead to the expected derivative (55 mg, 0.088 mmol, 100%) as an amorphous.
• Example 12 Sodium salt and trifluoroacetate of trans-8- (amino-methyl) -2- (3-amino-3-carboxy-propyl) -4,8-dihydro-5- (sulfooxy) -4,7 -methano-7H-pyrazolor3,4-e] [1,31 diazepin-6 (5H) -one
• Step D of Example 1 the derivative obtained in the preceding stage (92 mg, O.Bmmol), a mixture of dimethylformamide / CH 2 Cl 2 1/3 anhydrous (0.8 ml) and palladium 10% on charcoal at 50% water (43mg) lead to the expected debenzylated intermediate.
• the debenzylated intermediate, pyridine (380 ⁇ L) and the pyridine / trioxide sulphide complex (43 mg, 0.27 mmol) lead, after chromatography on a silica column (CH 2 Cl 2 / MeOH 90/10 eluent) to the expected salt (28 mg, 0.037mmol, 19%).
• Example 13 Sodium salt and trifluoroacetate salt of trans-8- (guanidino-methyl-4,4-dihydro-5- (sulfooxy) -4,7-methano-7H-pyrazolor-3,4-e] [1,3] diazepine 6 (5H) -one
• the compound obtained in the preceding stage (130 mg, 0.24 mmol) is dissolved in dichloromethane (12 ml).
• N, N-dimethylaminopyridine (15mg, 0.12mmol) is added, followed by di-tert-butyl dicarbonate (105mg, 0.48mmol).
• the medium is hydrolyzed with an aqueous solution of 10% tartaric acid (1 ⁇ L).
• the phases are separated, the aqueous phase is extracted with dichloromethane (10 mL). The organic phases are combined, washed with water and then with saturated NaCl solution, dried over MgSO 4 and concentrated to dryness.
• Step E of Example 1 the salt obtained in the preceding stage (50 mg, 0.07 mmol), DOWEX 50WX8 resin (3.5 g) and 2N sodium hydroxide (17.5 ml) lead to the expected sodium salt (42 mg). 0.064 mmol, 91%) as a white lyophilisate.
• Example 14 Sodium salt and trifluoroacetate salt of trans-8- (guanidino-methyl) -4,8-dmvdro-1-methyl-5- (sulfooxy) -4,7-methano-7H-pyrazolo [3,4- e] [1, 3] diazepin-6 (5H) -one
• the reaction mixture is stirred while allowing the temperature to rise gradually to room temperature.
• the medium is treated by addition of water (20OmL) and diluted with dichloromethane (10OmL). After stirring and decantation, the aqueous phase is extracted with dichloromethane. The organic phase is washed with saturated NaCl solution (20OmL), dried and then concentrated to dryness to give a white amorphous powder, which after chromatography leads to the expected derivative (8.25g, 21.2mmol, 66%).
• the aqueous phase is re-extracted with ethyl acetate (2 ⁇ 300 ml), the last extraction being carried out after saturation of the aqueous phase with NaCl.
• the organic phase is dried and concentrated.
• the deprotected piperidine intermediate is obtained in the form of a yellow oil (15.7 g, 49.4 mmol, 98%) which is taken up in acetonitrile (40 mL). To this mixture cooled to 0 ° C are added triethylamine (2 ImL, 151.2mmol), then the diphosgene (3.04mL, 25.2mmol) dripped over 30min.
• the residual mixture is taken up with ethyl acetate (20OmL), stirred and decanted.
• the aqueous phase is re-extracted with the ethyl acetate (10OmL).
• the organic phase is dried over magnesium sulfate and then concentrated to dryness.
• the light yellow powder obtained (6.6 g) is chromatographed on silica (eluent-ethyl acetate) to give the expected derivative (3.2 g, 10.18 mmol, 64%).
• the alcohol obtained in the preceding stage (2.76 g, 8.78 mmol) is dissolved in dichloromethane (100 mL) at room temperature under nitrogen and with stirring. After cooling to 0 ° C., triethylamine (1.83 mL, 13.17 mmol) is added, followed by dropwise addition of a solution of methanesulfonyl chloride (1.6 g, 14.05 mmol) in dichloromethane (100 mL). The ice bath is removed at the end of the addition. After stirring for one hour at room temperature, the reaction is treated with stirring with a 10% solution of NaH 2 PO 4 (8OmL). The aqueous phase is re-extracted with dichloromethane (50 mL). The organic phases are combined, dried and then concentrated under reduced pressure to give the expected derivative (3.44 g, 8.78 mmol, quantitative yield).
• 1,3-bis (tert-butoxycarbonyl) -2-methyl-2-thiopseudourea 141 mg, 0.48 mmol
• the water 0.5 ml
• the medium is concentrated under reduced pressure to give a pale yellow powder, which, after purification by chromatography on a silica column (eluent cyclohexane / sodium acetate). ethyl 5/5) leads to the expected product (152mg, 0.273mmol, 61%).
• the debenzylated intermediate is taken up in pyridine (ImL) in the presence of the pyridine / trioxide sulphide complex (82 mg, 0.511 mmol). After stirring overnight at room temperature, the medium is concentrated in vacuo. The crude reaction product is chromatographed on a silica column (gradient eluent C 2 Cl 2 / methanol 100/0 to 80/20) to give the expected derivative (62 mg, 0.1 mmol, 45%).
• Step E of Example 1 the derivative obtained in the preceding stage (62 mg, 100 mmol), DOWEX 50WX8 resin (62 g) and 2N sodium hydroxide (30OmL) give the expected derivative (57 mg, 0.1 mmol, 100%) as an amorphous white powder.
• Example 15 Sodium salt and trifluoroacetate salt of trans-8- (guanidino-methyl) -1-ethylcarbamoyl-4,8-dihydro-5- (sulfooxy) -4,7-methano-7H-pyrazolo [3, 4-e1 [1, 31 diazepin-6 (5H) -one Stage A trans [[[1-ethylcarbamoyl-4,5,6,8-tetrahydro-6-oxo-5- (phenylmethoxy) -4,7-methano-7H-pyrazolo [3,4-e] [1,3] ] bis-bis (1,1-dimethylethyl) diazepin-8-yl] methyl] -carbonimidoyl] carbamate and trans [[[2-ethylcarbamoyl-4,5,6,8-tetrahydro-6-oxo-5- bis-bis (1,1-dimethylethyl) -4- (7-phen
• the thick mixture obtained is taken up in water (5 ml) and then dichloromethane (100 ml) is added. After good agitation and decantation, the aqueous phase is extracted with dichloromethane. The organic phases are combined, washed with saturated NaCl solution, dried over magnesium sulphate and evaporated to dryness to give a beige solid.
• Step D of Example 1 the Nl derivative obtained in the preceding stage (150 mg, 0.245 mmol), dimethylformamide (0.36 ml), dichloromethane (1. imL) and palladium 10% on carbon at 50.degree. % water (78.2mg, 0.037mmol) lead to the expected debenzylated intermediate.
• the debenzylated intermediate, pyridine (0.74mL) and the pyridine / trioxide sulphide complex (78mg, 0.245mmol) lead, after chromatography on a silica column (2g, gradient eluent 100/0, 95/5, then 90/10 ) the expected derivative (78mg, 0.1 14mmol, 46.7%) as a white solid.
• Step E of Example 1 the salt obtained in the preceding stage (108 mg, 0.15 mmol) deposited in solution in water, DOWEX 50WX8 resin (23 g) and 2N sodium hydroxide (120 mL) lead to expected sodium salt (35mg, 0.056mmol, 35%) as a white lyophilisate.
• the sodium salt obtained in the preceding stage (18 mg, 0.028 mmol), dichloromethane (3 ml) and trifluoroacetic acid (1.5 ml) give the expected product.
• the suspension obtained by taking up the product in water is filtered to remove the insoluble material.
• the filtrate is frozen and lyophilized to give the expected product (12mg, 0.018mmol, 64.5%) as a slightly brown solid.
• reaction is carried out a second time on 150 mg (0.277 mmol) of substrate using 0.279 ml (1.94 mmol) of trimethylsilane isocyanate (added in 4 times over 6 days) to give 160 mg of crude product.
• the two crude batches are pooled and purified by chromatography on a silica column (10 g, eluent C ⁇ 2 Cl 2 / AcOEt 100/0, 95/05, 91/09 then 85/15). This makes it possible to isolate the expected compound substituted with N 2 (72 mg, 0.123 mmol, 25%) in the form of a white solid.
• Stage B 5 [[[2-Carbamoyl-4,5,6,8-tetrahydro-6-oxo-5- (sulfooxy) -4,7-methano-7H-pyrazolo] pyridinium salt; bis [bis (1,1-dimethylethyl)] [1,3] diazepin-8-yl] methyl] -carbonimidoyl] carbamate
• Step D of Example 1 the derivative obtained in the preceding stage (86 mg, 0.147 mmol), dimethylformamide (0.2 ⁇ mol), dichloromethane (0.64 ml) and palladium 10% on carbon at 50% by weight are used. water (47mg, 0.022mmol) lead to the expected debenzylated intermediate.
• Step D trans [[8- (guanidino-methyl) -2-carbamoyl-4,8-dihydro-5- (sulfooxy) -4,7-methano-7H-pyrazolo [3,4-e] [1,3] diazepin-6 (5H) -one
• the sodium salt obtained in the previous step 24mg, 0.04mmol
• dichloromethane 3mL
• 1 "trifluoroacetic acid (3mL) lead to the expected product.
• After evaporation in vacuo the product is taken up in water
• the suspension obtained is filtered off
• the solid is recovered and dried under vacuum overnight to give the expected compound (4.9 mg, 0.013 mmol, 32.5%) as a beige solid.
• the aqueous phase is extracted with ethyl acetate (50 mL).
• the organic phase is dried and then concentrated under reduced pressure to give an oil (2.2 g).
• the crude product is chromatographed on a silica column (eluent cyclohexane / ethyl acetate 5/5) to give the expected product (0.62 g, 1.49 mmol, 70%).
• the debenzylated intermediate (234 mg, 0.72 mmol) is taken up under nitrogen in anhydrous dimethylformamide (1.6 ml) in the presence of potassium carbonate (0.25 g, 0.1 mmol) and ethyl bromodifluoroacetate (0.373 ml, 2.89 mmol). .
• the reaction is stirred at room temperature overnight.
• the reaction mixture is then filtered and rinsed with ethyl acetate.
• the filtrate is washed three times with water, the organic phase is dried over magnesium sulfate and then concentrated under reduced pressure.
• Lithium hydroxide (0.017 g, 0.41 mmol) is added in two portions to a solution of the ester obtained in Step B of Example 10 (0.181 g, 0.41 mmol) in a tetrahydrofuran / water mixture (7.38 / 2.48mL) at 0 ° C. Stirring is continued at 0 ° C. for 1 h 30 min.
• the reaction medium is treated with an aqueous solution of 10% tartaric acid and extracted twice with ethyl acetate.
• the organic phase is dried over magnesium sulfate and then concentrated in vacuo to yield the expected acid (10 mg, 0.32 mmol, 79%) as an amorphous.
• Step C of Example 1 the derivative obtained in Step B of Example 1 (Ig, 2.5 mmol)), dichloromethane (131 mL), triethylamine (698 ⁇ L), diphosgene (453 ⁇ L) and N-Boc-hydrazine (1.158 g) yield, after chromatography on a silica column (CH 2 Cl 2 gradient eluent ZMeOH 100/0 to 95/5), the expected derivative (654 mg, 1.17 mmol mmol, 47 %).
• Step D of Example 1 the derivative obtained in the preceding stage (654 mg, 1.17 mmol), dimethylformamide (3.3 mL), dichloromethane (10 mL) and palladium 10% on carbon at 50% in water (262 mg) lead to the expected debenzylated intermediate.
• a suspension of 75 g of DOWEX 50WX8 resin in a 2N sodium hydroxide solution (375 ml) is stirred for 1 h and then poured onto a chromatography column.
• the column is conditioned with demineralised water until neutral pH.
• the derivative obtained (431 mg) is dissolved in H 2 O, deposited on the column, then eluted with H 2 O.
• the fractions containing the substrate are combined, frozen and lyophilized to yield the expected sodium salt (362 mg, 0.63 mmol, %) in the form of a white powder.
• composition for injection comprising:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Oncology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=40530144

Family Applications (2)

Family Applications After (1)

Country Status (19)

Families Citing this family (11)

Family Cites Families (17)

• 2008
  • 2008-10-10 FR FR0805602A patent/FR2937034B1/fr not_active Expired - Fee Related
• 2009
  • 2009-07-29 BR BRPI0919807A patent/BRPI0919807A2/pt not_active IP Right Cessation
  • 2009-07-29 CA CA2739776A patent/CA2739776A1/fr not_active Abandoned
  • 2009-07-29 PE PE2011000846A patent/PE20120054A1/es not_active Application Discontinuation
  • 2009-07-29 WO PCT/IB2009/006403 patent/WO2010041108A1/fr active Application Filing
  • 2009-07-29 JP JP2011530583A patent/JP2012505195A/ja not_active Ceased
  • 2009-07-29 CN CN200980146341.7A patent/CN102216307B/zh not_active Expired - Fee Related
  • 2009-07-29 EP EP09786084A patent/EP2358722A1/fr not_active Withdrawn
  • 2009-07-29 AU AU2009302149A patent/AU2009302149A1/en not_active Abandoned
  • 2009-07-29 EA EA201170546A patent/EA201170546A1/ru unknown
  • 2009-07-29 KR KR1020117009785A patent/KR20110067140A/ko not_active Application Discontinuation
  • 2009-07-29 EP EP14192364.9A patent/EP2853534A1/fr not_active Withdrawn
  • 2009-07-29 NZ NZ592168A patent/NZ592168A/xx not_active IP Right Cessation
  • 2009-07-29 MX MX2011003811A patent/MX2011003811A/es unknown
  • 2009-08-05 US US12/536,034 patent/US8148366B2/en not_active Expired - Fee Related
• 2011
  • 2011-04-05 ZA ZA2011/02497A patent/ZA201102497B/en unknown
  • 2011-04-06 IL IL212179A patent/IL212179A0/en unknown
  • 2011-04-07 EC EC2011010962A patent/ECSP11010962A/es unknown
  • 2011-04-08 CL CL2011000784A patent/CL2011000784A1/es unknown
  • 2011-04-08 CO CO11043787A patent/CO6382121A2/es not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events